Objective: To investigate the effect of serum glycosylated hemoglobin (HbA1c) on the outcomes of ranibizumab therapy for diabetic macular edema (DME).
Design: Retrospective cohort study.
Participants: Patients receiving ranibizumab injections for centre-involving DME in a National Health Service setting.